Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features

The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as “amplified,” inclusive of cases with a HER2 copy number less than 4. The 2018 A...

Full description

Saved in:

Bibliographic Details
Published in:	Human pathology Vol. 83; pp. 7 - 13
Main Authors:	Zare, Somaye Y., Lin, Leo, Alghamdi, Abrar G., Daehne, Svenja, Roma, Andres A., Hasteh, Farnaz, Dell'Aquila, Marie, Fadare, Oluwole
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.01.2019 Elsevier Limited
Subjects:	Adult Aged Aged, 80 and over Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - classification Breast Neoplasms - genetics Breast Neoplasms - pathology Centromere enumeration probe for chromosome 17 Chromosome 17 monosomy Chromosomes Chromosomes, Human, Pair 17 - genetics Female Fluorescence in situ hybridization Gene Dosage Gene Expression Profiling - methods Genes, erbB-2 Human epidermal growth factor receptor 2 Humans Hybridization Immunohistochemistry Lymphatic system Middle Aged Receptor, ErbB-2 - analysis Receptor, ErbB-2 - genetics Tumors Young Adult Chromosome 17 monosomy Breast cancer Human epidermal growth factor receptor 2 Centromere enumeration probe for chromosome 17 Fluorescence in situ hybridization
ISSN:	0046-8177, 1532-8392, 1532-8392
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as “amplified,” inclusive of cases with a HER2 copy number less than 4. The 2018 ASCO/CAP update assigns HER2/neu status for the latter group in a fashion that is highly dependent on the associated immunohistochemical findings. Herein, the authors define the frequency, immunohistochemical correlates, and other clinicopathological features of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2/neu copy number less than 4 (group A), based on an analysis of an institutional cohort assessed for HER2/neu status by both florescence in situ hybridization and immunohistochemistry and scored using 2013 ASCO/CAP criteria. Group A cases were compared with a group B of HER2/neu-amplified breast cancers with a HER2/neu copy number of 4 or greater regarding a variety of clinicopathological features. One hundred sixty-nine (14%) of 1201 cases were HER2/neu amplified, 18 (10.7%) in group A and 151 (89.3%) in group B. By immunohistochemistry, 61.1% of group A cases were HER2/neu negative, 7 (38.9%) were equivocal, and none were positive. In contrast, 66.9% of group B cases were HER2 positive (3+). We could not demonstrate statistically significant differences between the 2 groups regarding standard clinicopathological variables. In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria. They are predominantly HER2/neu negative by immunohistochemistry, which suggests that they are biologically different from classically HER2/neu-amplified cases and which validates the 2018 ASCO/CAP guideline against automatically classifying such cases as HER2/neu amplified. •Breast cancers with HER2/CEP17 ratio of 2 or greater and HER2 copy number less than 4 account for 1.5% of breast cancers.•Sixty-one percent of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2 copy number less than 4 are HER2 negative by IHC.•None of the breast cancers with HER2/CEP17 ratio of 2 or greater and HER2 copy number less than 4 were HER2 positive by IHC.•The findings are supportive of the 2018 ASCO/CAP guideline classifying these cases as HER2 negative.
AbstractList	The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as "amplified," inclusive of cases with a HER2 copy number less than 4. The 2018 ASCO/CAP update assigns HER2/neu status for the latter group in a fashion that is highly dependent on the associated immunohistochemical findings. Herein, the authors define the frequency, immunohistochemical correlates, and other clinicopathological features of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2/neu copy number less than 4 (group A), based on an analysis of an institutional cohort assessed for HER2/neu status by both florescence in situ hybridization and immunohistochemistry and scored using 2013 ASCO/CAP criteria. Group A cases were compared with a group B of HER2/neu-amplified breast cancers with a HER2/neu copy number of 4 or greater regarding a variety of clinicopathological features. One hundred sixty-nine (14%) of 1201 cases were HER2/neu amplified, 18 (10.7%) in group A and 151 (89.3%) in group B. By immunohistochemistry, 61.1% of group A cases were HER2/neu negative, 7 (38.9%) were equivocal, and none were positive. In contrast, 66.9% of group B cases were HER2 positive (3+). We could not demonstrate statistically significant differences between the 2 groups regarding standard clinicopathological variables. In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria. They are predominantly HER2/neu negative by immunohistochemistry, which suggests that they are biologically different from classically HER2/neu-amplified cases and which validates the 2018 ASCO/CAP guideline against automatically classifying such cases as HER2/neu amplified.The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as "amplified," inclusive of cases with a HER2 copy number less than 4. The 2018 ASCO/CAP update assigns HER2/neu status for the latter group in a fashion that is highly dependent on the associated immunohistochemical findings. Herein, the authors define the frequency, immunohistochemical correlates, and other clinicopathological features of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2/neu copy number less than 4 (group A), based on an analysis of an institutional cohort assessed for HER2/neu status by both florescence in situ hybridization and immunohistochemistry and scored using 2013 ASCO/CAP criteria. Group A cases were compared with a group B of HER2/neu-amplified breast cancers with a HER2/neu copy number of 4 or greater regarding a variety of clinicopathological features. One hundred sixty-nine (14%) of 1201 cases were HER2/neu amplified, 18 (10.7%) in group A and 151 (89.3%) in group B. By immunohistochemistry, 61.1% of group A cases were HER2/neu negative, 7 (38.9%) were equivocal, and none were positive. In contrast, 66.9% of group B cases were HER2 positive (3+). We could not demonstrate statistically significant differences between the 2 groups regarding standard clinicopathological variables. In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria. They are predominantly HER2/neu negative by immunohistochemistry, which suggests that they are biologically different from classically HER2/neu-amplified cases and which validates the 2018 ASCO/CAP guideline against automatically classifying such cases as HER2/neu amplified. The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as “amplified,” inclusive of cases with a HER2 copy number less than 4. The 2018 ASCO/CAP update assigns HER2/neu status for the latter group in a fashion that is highly dependent on the associated immunohistochemical findings. Herein, the authors define the frequency, immunohistochemical correlates, and other clinicopathological features of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2/neu copy number less than 4 (group A), based on an analysis of an institutional cohort assessed for HER2/neu status by both florescence in situ hybridization and immunohistochemistry and scored using 2013 ASCO/CAP criteria. Group A cases were compared with a group B of HER2/neu-amplified breast cancers with a HER2/neu copy number of 4 or greater regarding a variety of clinicopathological features. One hundred sixty-nine (14%) of 1201 cases were HER2/neu amplified, 18 (10.7%) in group A and 151 (89.3%) in group B. By immunohistochemistry, 61.1% of group A cases were HER2/neu negative, 7 (38.9%) were equivocal, and none were positive. In contrast, 66.9% of group B cases were HER2 positive (3+). We could not demonstrate statistically significant differences between the 2 groups regarding standard clinicopathological variables. In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria. They are predominantly HER2/neu negative by immunohistochemistry, which suggests that they are biologically different from classically HER2/neu-amplified cases and which validates the 2018 ASCO/CAP guideline against automatically classifying such cases as HER2/neu amplified. •Breast cancers with HER2/CEP17 ratio of 2 or greater and HER2 copy number less than 4 account for 1.5% of breast cancers.•Sixty-one percent of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2 copy number less than 4 are HER2 negative by IHC.•None of the breast cancers with HER2/CEP17 ratio of 2 or greater and HER2 copy number less than 4 were HER2 positive by IHC.•The findings are supportive of the 2018 ASCO/CAP guideline classifying these cases as HER2 negative. The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as "amplified," inclusive of cases with a HER2 copy number less than 4. The 2018 ASCO/CAP update assigns HER2/neu status for the latter group in a fashion that is highly dependent on the associated immunohistochemical findings. Herein, the authors define the frequency, immunohistochemical correlates, and other clinicopathological features of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2/neu copy number less than 4 (group A), based on an analysis of an institutional cohort assessed for HER2/neu status by both florescence in situ hybridization and immunohistochemistry and scored using 2013 ASCO/CAP criteria. Group A cases were compared with a group B of HER2/neu-amplified breast cancers with a HER2/neu copy number of 4 or greater regarding a variety of clinicopathological features. One hundred sixty-nine (14%) of 1201 cases were HER2/neu amplified, 18 (10.7%) in group A and 151 (89.3%) in group B. By immunohistochemistry, 61.1% of group A cases were HER2/neu negative, 7 (38.9%) were equivocal, and none were positive. In contrast, 66.9% of group B cases were HER2 positive (3+). We could not demonstrate statistically significant differences between the 2 groups regarding standard clinicopathological variables. In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria. They are predominantly HER2/neu negative by immunohistochemistry, which suggests that they are biologically different from classically HER2/neu-amplified cases and which validates the 2018 ASCO/CAP guideline against automatically classifying such cases as HER2/neu amplified. SummaryThe 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ hybridization dual-probe HER2/CEP17 ratio of 2 or greater as “amplified,” inclusive of cases with a HER2 copy number less than 4. The 2018 ASCO/CAP update assigns HER2/neu status for the latter group in a fashion that is highly dependent on the associated immunohistochemical findings. Herein, the authors define the frequency, immunohistochemical correlates, and other clinicopathological features of breast cancers with HER2/CEP17 ratio of 2 or greater and HER2/neu copy number less than 4 (group A), based on an analysis of an institutional cohort assessed for HER2/neu status by both florescence in situ hybridization and immunohistochemistry and scored using 2013 ASCO/CAP criteria. Group A cases were compared with a group B of HER2/neu-amplified breast cancers with a HER2/neu copy number of 4 or greater regarding a variety of clinicopathological features. One hundred sixty-nine (14%) of 1201 cases were HER2/neu amplified, 18 (10.7%) in group A and 151 (89.3%) in group B. By immunohistochemistry, 61.1% of group A cases were HER2/neu negative, 7 (38.9%) were equivocal, and none were positive. In contrast, 66.9% of group B cases were HER2 positive (3+). We could not demonstrate statistically significant differences between the 2 groups regarding standard clinicopathological variables. In summary, our group A cases account for 1.5% of breast cancers, and 10.7% of all HER2/neu-amplified cancers classified as such based on 2013 ASCO/CAP criteria. They are predominantly HER2/neu negative by immunohistochemistry, which suggests that they are biologically different from classically HER2/neu-amplified cases and which validates the 2018 ASCO/CAP guideline against automatically classifying such cases as HER2/neu amplified.
Author	Dell'Aquila, Marie Hasteh, Farnaz Daehne, Svenja Lin, Leo Alghamdi, Abrar G. Roma, Andres A. Fadare, Oluwole Zare, Somaye Y.
Author_xml	– sequence: 1 givenname: Somaye Y. surname: Zare fullname: Zare, Somaye Y. – sequence: 2 givenname: Leo surname: Lin fullname: Lin, Leo – sequence: 3 givenname: Abrar G. surname: Alghamdi fullname: Alghamdi, Abrar G. – sequence: 4 givenname: Svenja surname: Daehne fullname: Daehne, Svenja – sequence: 5 givenname: Andres A. surname: Roma fullname: Roma, Andres A. – sequence: 6 givenname: Farnaz surname: Hasteh fullname: Hasteh, Farnaz – sequence: 7 givenname: Marie surname: Dell'Aquila fullname: Dell'Aquila, Marie – sequence: 8 givenname: Oluwole surname: Fadare fullname: Fadare, Oluwole email: oluwole.fadare@gmail.com
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30121371$$D View this record in MEDLINE/PubMed
BookMark	eNqFkstu1DAUhi1URKeFRwBZYsOiM_UljhMQCxgNFKkSCMHacpyTiYfEntpO0bwdj4bn0k03lWxZsr__PxefC3TmvAOEXlOyoISW15tFP41bnfoFI7RakLyIeIZmVHA2r3jNztCMkKKcV1TKc3QR44YQSkUhXqBzTiijXNIZ-vc5gI4JG-0MhIj_2tRjjW9WP9n1cvWDShx0sh77DrMFwT7gdRYkCFi7Nm-s7yHoNRwU2PjtDrtpbPJ7VgwQI059poqs3eZLA8PwHncB7iZwZneF7ThOzvc2Jm96GK3RQ3YJAYZ9WHd1CGMG62z2ztX6wa8PUJezmALEl-h5p4cIr07nJfr9ZfVreTO__f712_LT7dzwmqa5qAwxghW8JbQzvGOlkJrS0tS8lqzV3DBGpGyY6ICWINuygqITjWzqVta05pfo3dF3G3xOPiY12rgvRzvwU1SM1IQXBS2LjL59hG78FFzOTjEqC8l4IUSm3pyoqRmhVdtgRx126uFvMvDhCJjgYwzQKWPToSspaDsoStR-EtRGnSZB7SdBkbzI3l48Uj8EeEr38aiD3Mx7C0Edu6-HP7BTrbdP6P8D76rPHA
CitedBy_id	crossref_primary_10_1016_j_clbc_2023_02_006 crossref_primary_10_1038_s41379_020_0555_7 crossref_primary_10_1093_ajcp_aqz061 crossref_primary_10_1016_j_humpath_2020_01_003 crossref_primary_10_1016_j_anndiagpath_2022_151935 crossref_primary_10_1038_s41379_020_0519_y crossref_primary_10_1038_s41598_019_53003_w crossref_primary_10_1038_s41379_019_0295_8 crossref_primary_10_1186_s12885_023_10531_z crossref_primary_10_1097_PGP_0000000000000943 crossref_primary_10_1007_s11912_020_0901_4 crossref_primary_10_3390_cancers17060946 crossref_primary_10_4103_jpi_jpi_52_19 crossref_primary_10_3389_fonc_2020_00985
Cites_doi	10.1200/JCO.1999.17.9.2639 10.1200/JCO.2009.26.2154 10.1200/JCO.2016.66.6693 10.1200/JCO.2008.19.7939 10.1038/modpathol.2015.112 10.1126/science.3798106 10.1056/NEJM200103153441101 10.1001/jama.291.16.1972 10.5858/arpa.2016-0009-OA 10.1200/JCO.2015.61.8983 10.1200/JCO.1997.15.8.2894 10.1038/modpathol.2016.175 10.1097/PAS.0000000000001106 10.1200/JCO.2013.50.9984 10.1200/JCO.2013.53.9213 10.1007/s10549-017-4520-1 10.1093/ajcp/aqw224 10.1016/S1470-2045(09)70063-4 10.1200/JCO.2018.77.8738 10.5858/2007-131-18-ASOCCO 10.1200/JCO.2014.55.0673 10.1016/j.clbc.2014.11.009
ContentType	Journal Article
Copyright	2018 Elsevier Inc. Copyright © 2018 Elsevier Inc. All rights reserved. Copyright Elsevier Limited Jan 2019
Copyright_xml	– notice: 2018 Elsevier Inc. – notice: Copyright © 2018 Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Limited Jan 2019
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8
DOI	10.1016/j.humpath.2018.08.005
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni)
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1532-8392
EndPage	13
ExternalDocumentID	30121371 10_1016_j_humpath_2018_08_005 S0046817718303095
Genre	Journal Article
GroupedDBID	--- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 3O- 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQOH AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI CAG COF DU5 EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDY HMK HMO HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OG0 OS0 OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSZ SV3 T5K UGJ UHS UNMZH UV1 WUQ X7M Z5R ZGI ~G- ~HD 9DU AAYXX CITATION AFCTW AGCQF AGRNS CGR CUY CVF ECM EIF NPM RIG K9. 7X8
ID	FETCH-LOGICAL-c391t-58c0c5243d01fc3f2657a116c93972da3c22077b25fe16e7d68e4f5b7b9d79193
ISICitedReferencesCount	13
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000459234800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0046-8177 1532-8392
IngestDate	Sun Sep 28 01:55:24 EDT 2025 Tue Oct 07 06:00:12 EDT 2025 Mon Jul 21 05:13:03 EDT 2025 Tue Nov 18 22:38:10 EST 2025 Sat Nov 29 03:41:11 EST 2025 Tue Oct 14 19:31:12 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Keywords	Chromosome 17 monosomy Breast cancer Human epidermal growth factor receptor 2 Centromere enumeration probe for chromosome 17 Fluorescence in situ hybridization
Language	English
License	Copyright © 2018 Elsevier Inc. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c391t-58c0c5243d01fc3f2657a116c93972da3c22077b25fe16e7d68e4f5b7b9d79193
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
PMID	30121371
PQID	2174723455
PQPubID	105547
PageCount	7
ParticipantIDs	proquest_miscellaneous_2090344164 proquest_journals_2174723455 pubmed_primary_30121371 crossref_citationtrail_10_1016_j_humpath_2018_08_005 crossref_primary_10_1016_j_humpath_2018_08_005 elsevier_clinicalkey_doi_10_1016_j_humpath_2018_08_005
PublicationCentury	2000
PublicationDate	January 2019 2019-01-00 20190101
PublicationDateYYYYMMDD	2019-01-01
PublicationDate_xml	– month: 01 year: 2019 text: January 2019
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Philadelphia
PublicationTitle	Human pathology
PublicationTitleAlternate	Hum Pathol
PublicationYear	2019
Publisher	Elsevier Inc Elsevier Limited
Publisher_xml	– name: Elsevier Inc – name: Elsevier Limited
References	Wolff, Hammond, Allison, Harvey, Mangu, Bartlett, Bilous, Ellis, Fitzgibbons, Hanna, Jenkins, Press, Spears, Vance, Viale, McShane, Dowsett (bb0080) 2018 Jul 10; 36 Solomon, Dell'Aquila, Fadare, Hasteh (bb0085) 2017; 147 Shah, Wiktor, Meyer (bb0075) 2016; 34 Brunelli, Nottegar, Bogina (bb0095) 2015; 5 Reinholz, Bruzek, Visscher (bb0100) 2009; 10 Slamon, Leyland-Jones, Shak (bb0035) 2001; 344 Bhargava, Dabbs (bb0060) 2014; 32 Dowsett, Procter, McCaskill-Stevens (bb0055) 2009; 27 Ballard, Jalikis, Krings (bb0050) 2017; 30 Press, Sauter, Buyse (bb0070) 2016; 34 Zare, Lin, Alghamdi, Daehne, Roma, Hasteh, Dell'Aquila, Fadare (bb0090) 2018 Sep; 42 Stoss, Scheel, Nagelmeier (bb0115) 2015; 28 Page, Wen, Brogi (bb0045) 2018; 167 Press, Villalobos, Santiago (bb0065) 2016; 140 Wolff, Hammond, Hicks (bb0025) 2013; 31 Press, Bernstein, Thomas (bb0010) 1997; 15 Ballinger, Sanders, Abramson (bb0030) 2015; 15 Wolff, Hammond, Hicks, Dowsett, Hayes, McShane (bb0105) 2014; 32 Slamon, Clark, Wong (bb0005) 1987; 235 Cobleigh, Vogel, Tripathy (bb0020) 1999; 17 Perez, Reinholz, Hillman (bb0110) 2010; 28 Wolff, Hammond, Schwartz (bb0040) 2007; 131 Yaziji, Goldstein, Barry (bb0015) 2004; 291 Bhargava (10.1016/j.humpath.2018.08.005_bb0060) 2014; 32 Yaziji (10.1016/j.humpath.2018.08.005_bb0015) 2004; 291 Ballinger (10.1016/j.humpath.2018.08.005_bb0030) 2015; 15 Wolff (10.1016/j.humpath.2018.08.005_bb0025) 2013; 31 Press (10.1016/j.humpath.2018.08.005_bb0010) 1997; 15 Ballard (10.1016/j.humpath.2018.08.005_bb0050) 2017; 30 Press (10.1016/j.humpath.2018.08.005_bb0065) 2016; 140 Shah (10.1016/j.humpath.2018.08.005_bb0075) 2016; 34 Zare (10.1016/j.humpath.2018.08.005_bb0090) 2018; 42 Solomon (10.1016/j.humpath.2018.08.005_bb0085) 2017; 147 Perez (10.1016/j.humpath.2018.08.005_bb0110) 2010; 28 Stoss (10.1016/j.humpath.2018.08.005_bb0115) 2015; 28 Wolff (10.1016/j.humpath.2018.08.005_bb0080) 2018; 36 Brunelli (10.1016/j.humpath.2018.08.005_bb0095) 2015; 5 Cobleigh (10.1016/j.humpath.2018.08.005_bb0020) 1999; 17 Wolff (10.1016/j.humpath.2018.08.005_bb0040) 2007; 131 Page (10.1016/j.humpath.2018.08.005_bb0045) 2018; 167 Slamon (10.1016/j.humpath.2018.08.005_bb0035) 2001; 344 Reinholz (10.1016/j.humpath.2018.08.005_bb0100) 2009; 10 Dowsett (10.1016/j.humpath.2018.08.005_bb0055) 2009; 27 Press (10.1016/j.humpath.2018.08.005_bb0070) 2016; 34 Slamon (10.1016/j.humpath.2018.08.005_bb0005) 1987; 235 Wolff (10.1016/j.humpath.2018.08.005_bb0105) 2014; 32
References_xml	– volume: 147 start-page: 432 year: 2017 end-page: 437 ident: bb0085 article-title: /neu status determination in breast cancer: a single institutional experience using a dual-testing approach with immunohistochemistry and fluorescence in situ hybridization publication-title: Am J Clin Pathol – volume: 31 start-page: 3997 year: 2013 end-page: 4013 ident: bb0025 article-title: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update publication-title: J Clin Oncol – volume: 167 start-page: 547 year: 2018 end-page: 554 ident: bb0045 article-title: Monosomy 17 in potentially curable publication-title: Breast Cancer Res Treat – volume: 131 start-page: 18 year: 2007 end-page: 43 ident: bb0040 article-title: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer publication-title: Arch Pathol Lab Med – volume: 28 start-page: 1528 year: 2015 end-page: 1534 ident: bb0115 article-title: Impact of updated publication-title: Mod Pathol – volume: 34 start-page: 3518 year: 2016 end-page: 3528 ident: bb0070 article-title: gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer international Research Group clinical trials publication-title: J Clin Oncol – volume: 235 start-page: 177 year: 1987 end-page: 182 ident: bb0005 article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene publication-title: Science – volume: 291 start-page: 1972 year: 2004 end-page: 1977 ident: bb0015 article-title: HER-2 testing in breast cancer using parallel tissue-based methods publication-title: JAMA – volume: 27 start-page: 2962 year: 2009 end-page: 2969 ident: bb0055 article-title: Disease-free survival according to degree of publication-title: J Clin Oncol – volume: 344 start-page: 783 year: 2001 end-page: 792 ident: bb0035 article-title: Use of chemotherapy, plus a monoclonal antibody against publication-title: N Engl J Med – volume: 15 start-page: 171 year: 2015 end-page: 180 ident: bb0030 article-title: Current publication-title: Clin Breast Cancer – volume: 42 start-page: 1208 year: 2018 Sep end-page: 1215 ident: bb0090 article-title: Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe publication-title: Am J Surg Pathol – volume: 34 start-page: 3502 year: 2016 end-page: 3510 ident: bb0075 article-title: Change in pattern of publication-title: J Clin Oncol – volume: 5 start-page: 2212 year: 2015 end-page: 2221 ident: bb0095 article-title: Monosomy of chromosome 17 in breast cancer during interpretation of publication-title: Am J Cancer Res – volume: 10 start-page: 267 year: 2009 end-page: 277 ident: bb0100 article-title: Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response publication-title: Lancet Oncol – volume: 32 start-page: 1855 year: 2014 ident: bb0060 article-title: Interpretation of human epidermal growth factor receptor 2 ( publication-title: J Clin Oncol – volume: 140 start-page: 1250 year: 2016 end-page: 1258 ident: bb0065 article-title: Assessing the new American Society of Clinical Oncology/College of American Pathologists guidelines for publication-title: Arch Pathol Lab Med – volume: 28 start-page: 4307 year: 2010 end-page: 4315 ident: bb0110 article-title: and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial publication-title: J Clin Oncol – volume: 15 start-page: 2894 year: 1997 end-page: 2904 ident: bb0010 article-title: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas publication-title: J Clin Oncol – volume: 32 start-page: 1857 year: 2014 end-page: 1859 ident: bb0105 article-title: Reply to R. Bhargava et al and K. Lambein et al publication-title: J Clin Oncol – volume: 17 start-page: 2639 year: 1999 end-page: 2648 ident: bb0020 article-title: Multinational study of the efficacy and safety of humanized anti- publication-title: J Clin Oncol – volume: 30 start-page: 227 year: 2017 end-page: 235 ident: bb0050 article-title: 'Non-classical' publication-title: Mod Pathol – volume: 36 start-page: 2105 year: 2018 Jul 10 end-page: 2122 ident: bb0080 article-title: Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update publication-title: J Clin Oncol – volume: 17 start-page: 2639 year: 1999 ident: 10.1016/j.humpath.2018.08.005_bb0020 article-title: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.9.2639 – volume: 28 start-page: 4307 year: 2010 ident: 10.1016/j.humpath.2018.08.005_bb0110 article-title: HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial publication-title: J Clin Oncol doi: 10.1200/JCO.2009.26.2154 – volume: 34 start-page: 3518 year: 2016 ident: 10.1016/j.humpath.2018.08.005_bb0070 article-title: HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer international Research Group clinical trials publication-title: J Clin Oncol doi: 10.1200/JCO.2016.66.6693 – volume: 27 start-page: 2962 year: 2009 ident: 10.1016/j.humpath.2018.08.005_bb0055 article-title: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.7939 – volume: 28 start-page: 1528 year: 2015 ident: 10.1016/j.humpath.2018.08.005_bb0115 article-title: Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data publication-title: Mod Pathol doi: 10.1038/modpathol.2015.112 – volume: 235 start-page: 177 year: 1987 ident: 10.1016/j.humpath.2018.08.005_bb0005 article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene publication-title: Science doi: 10.1126/science.3798106 – volume: 344 start-page: 783 year: 2001 ident: 10.1016/j.humpath.2018.08.005_bb0035 article-title: Use of chemotherapy, plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N Engl J Med doi: 10.1056/NEJM200103153441101 – volume: 291 start-page: 1972 year: 2004 ident: 10.1016/j.humpath.2018.08.005_bb0015 article-title: HER-2 testing in breast cancer using parallel tissue-based methods publication-title: JAMA doi: 10.1001/jama.291.16.1972 – volume: 140 start-page: 1250 year: 2016 ident: 10.1016/j.humpath.2018.08.005_bb0065 article-title: Assessing the new American Society of Clinical Oncology/College of American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: experience of an academic consultation practice publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2016-0009-OA – volume: 5 start-page: 2212 year: 2015 ident: 10.1016/j.humpath.2018.08.005_bb0095 article-title: Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification publication-title: Am J Cancer Res – volume: 34 start-page: 3502 year: 2016 ident: 10.1016/j.humpath.2018.08.005_bb0075 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.8983 – volume: 15 start-page: 2894 year: 1997 ident: 10.1016/j.humpath.2018.08.005_bb0010 article-title: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.8.2894 – volume: 30 start-page: 227 year: 2017 ident: 10.1016/j.humpath.2018.08.005_bb0050 article-title: 'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study publication-title: Mod Pathol doi: 10.1038/modpathol.2016.175 – volume: 42 start-page: 1208 issue: 9 year: 2018 ident: 10.1016/j.humpath.2018.08.005_bb0090 article-title: Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000001106 – volume: 31 start-page: 3997 issue: 31 year: 2013 ident: 10.1016/j.humpath.2018.08.005_bb0025 article-title: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.2013.50.9984 – volume: 32 start-page: 1855 year: 2014 ident: 10.1016/j.humpath.2018.08.005_bb0060 article-title: Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 Guidelines [letter] publication-title: J Clin Oncol doi: 10.1200/JCO.2013.53.9213 – volume: 167 start-page: 547 year: 2018 ident: 10.1016/j.humpath.2018.08.005_bb0045 article-title: Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4520-1 – volume: 147 start-page: 432 year: 2017 ident: 10.1016/j.humpath.2018.08.005_bb0085 article-title: HER2/neu status determination in breast cancer: a single institutional experience using a dual-testing approach with immunohistochemistry and fluorescence in situ hybridization publication-title: Am J Clin Pathol doi: 10.1093/ajcp/aqw224 – volume: 10 start-page: 267 year: 2009 ident: 10.1016/j.humpath.2018.08.005_bb0100 article-title: Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70063-4 – volume: 36 start-page: 2105 issue: 20 year: 2018 ident: 10.1016/j.humpath.2018.08.005_bb0080 article-title: Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update publication-title: J Clin Oncol doi: 10.1200/JCO.2018.77.8738 – volume: 131 start-page: 18 year: 2007 ident: 10.1016/j.humpath.2018.08.005_bb0040 article-title: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer publication-title: Arch Pathol Lab Med doi: 10.5858/2007-131-18-ASOCCO – volume: 32 start-page: 1857 year: 2014 ident: 10.1016/j.humpath.2018.08.005_bb0105 article-title: Reply to R. Bhargava et al and K. Lambein et al publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.0673 – volume: 15 start-page: 171 year: 2015 ident: 10.1016/j.humpath.2018.08.005_bb0030 article-title: Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy publication-title: Clin Breast Cancer doi: 10.1016/j.clbc.2014.11.009
SSID	ssj0011545
Score	2.3480947
Snippet	The 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence in situ... SummaryThe 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines classified breast cancers with a fluorescence...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	7
SubjectTerms	Adult Aged Aged, 80 and over Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - classification Breast Neoplasms - genetics Breast Neoplasms - pathology Centromere enumeration probe for chromosome 17 Chromosome 17 monosomy Chromosomes Chromosomes, Human, Pair 17 - genetics Female Fluorescence in situ hybridization Gene Dosage Gene Expression Profiling - methods Genes, erbB-2 Human epidermal growth factor receptor 2 Humans Hybridization Immunohistochemistry Lymphatic system Middle Aged Receptor, ErbB-2 - analysis Receptor, ErbB-2 - genetics Tumors Young Adult
Title	Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0046817718303095 https://www.ncbi.nlm.nih.gov/pubmed/30121371 https://www.proquest.com/docview/2174723455 https://www.proquest.com/docview/2090344164
Volume	83
WOSCitedRecordID	wos000459234800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1532-8392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011545 issn: 0046-8177 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ1fb9MwEMCtbkPTXhD_KYzJSLxl6fLfDm9lFA1UpgkGqniJEsdZV7VJ1XbT9u34Bnwl7uw4LVKrwQMPjdo4ThrdL-fz5e5MyJvIEawomG_zEMy3AEwAO8tFZOcxywKRpTJVUb7f--z0lA8G8Vmr9cvkwlyPWVnym5t4-l9FDftA2Jg6-w_ibk4KO-A7CB22IHbY_pXg32GY-QKjuQQm5-rkNeuk9wVroB73zlxmKamjmeh1HAxIv0DLUc7qwq1WCveMoTzYxxLV9NbS64ZgjzFqRnS3WwH0ncJOdP2jX6GY6ahsJbVLTDupVDFjYUoSCFwIRIfemZhRnZdZ4bLIjRIupKo1Ol81m_WrBnNY8xbgR1p70KtJeiutxirv68IIfVk1PI8vhukkV6ELXXQQLNcUe5_KoXbrfgXFP0pX_SCYetX4QaTR3aDc_fgP5c79Fe3M1o4Z2n0x6gzh-YH7wHA_rsq6qnzwxQoy04lixld18Ji7HEKbwEbTtEV2PBbGoGZ3uh97g0_Niy20WJeJZEdrr7pHds15NllLm2ZDyio6f0Du19MZ2tUYPiQtWT4iu5_rgI3H5KemkdY0UqSRphTJOlIsUsUirQoKLNJqRmsWKeABH1qzqHpQZJFqFrEHskiRRQosUmCRIotvaUPiIV3DIV3h8FBdZg2F1FD4hHz70Ds_PrHrRUNs4cfuwg65cEToBX7uuIXwCy8KWeq6kYjB8vby1Bee5zCWeWEh3UiyPOIyKMKMZXHOYpjOPCXbZVXK54T6XApcPYJnPAsKXnD4HbCAw5Qj8mXgtElghJOIuqI-LuwyTkzo5CipxZugeBNc8NUJ26TTdJvqkjJ3dYiM5BOTLw0jfAIA39Vx33CS1BpqnqAPgnl-EELz66YZBhUUUVrK6gqOQe8tTJSioE2eab6av2rQfLGx5SXZWz6g-2R7MbuSr8g9cb24nM8OyBYb8IP6ufgNEjHzHw
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Breast+cancers+with+a+HER2%2FCEP17+ratio+of+2.0+or+greater+and+an+average+HER2+copy+number+of+less+than+4.0+per+cell%3A+frequency%2C+immunohistochemical+correlation%2C+and+clinicopathological+features&rft.jtitle=Human+pathology&rft.au=Zare%2C+Somaye+Y&rft.au=Lin%2C+Leo&rft.au=Alghamdi%2C+Abrar+G&rft.au=Daehne%2C+Svenja&rft.date=2019-01-01&rft.eissn=1532-8392&rft.volume=83&rft.spage=7&rft_id=info:doi/10.1016%2Fj.humpath.2018.08.005&rft_id=info%3Apmid%2F30121371&rft.externalDocID=30121371
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0046-8177&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0046-8177&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0046-8177&client=summon